Quantcast

Latest Biomedical Advanced Research and Development Authority Stories

2014-09-19 08:25:40

PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute...

2014-09-09 08:30:50

New patent includes composition of matter claims PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the US Patent and Trademark Office (US PTO) granted patent 8,808,710 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine...

2014-09-08 08:29:28

Presentation to be Webcast Live, 1:15 PM EDT, September 9th PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16(th) Annual Rodman & Renshaw Global...

2014-08-11 08:28:46

PRINCETON, N.J., Aug. 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the second quarter and six months ended June 30, 2014. Soligenix's revenues for the quarter and six months ended June 30,...

2014-08-01 08:26:07

Awarded $2.1 million in additional funding PRINCETON, N.J., Aug. 1, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to...

2014-06-17 12:28:42

MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its contract with the Company (contract number HHS0100200900106C) to support development, scale-up and expanded licensure of the Company's influenza vaccines, Flublok® (seasonal) and Panblok® (pandemic). Option Period 2 has a budget of $50.6 million and will run through December 31, 2015. The...

2014-05-29 12:28:35

ANNAPOLIS, Md., May 29, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax(®) anthrax vaccine program were presented at the 114(th) General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts. In a poster presentation entitled "Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine," Dr. Bradford Powell,...

2014-05-12 08:31:13

PRINCETON, N.J., May 12, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the first quarter ended March 31, 2014. Soligenix's revenues for the quarter ended March 31, 2014 were $0.9 million as...

2014-05-02 12:26:44

CLEVELAND, May 2, 2014 /PRNewswire/ -- Arteriocyte, Inc., a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts, announced approval from the Federal Drug Administration (FDA) to initiate a Phase I, clinical trial using its MAGELLAN(®) Bio-Bandage((TM) )technology in the treatment of Acute Deep Partial Thickness Thermal Injuries. The FDA Investigational Device Exemption (IDE 15921) allows Arteriocyte to initiate clinical evaluation of Autologous...

2014-04-08 08:32:45

Appoints Larry Gyenes, Formerly of Columbia Laboratories, as Chief Financial Officer PINE BROOK, N.J., April 8, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the commercial manufacturing process for ETI-204, an anthrax antitoxin currently undergoing Phase 3 clinical trials in healthy volunteers....


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.